IFx-Hu2.0 is named as an intervention in 2 current clinical trials in our USA register. 2 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is TuHURA Biosciences, Inc. The most-studied condition is Advanced Or Metastatic Merkel Cell Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928 · ClinicalTrials.gov ↗ · Advanced Or Metastatic Merkel Cell Carcinoma
|
Phase 2/3 | Recruiting | TuHURA Biosciences, Inc. | USA |
|
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
NCT06940440 · Advanced Or Metastatic Merkel Cell Carcinoma
|
Phase 1 | Recruiting | TuHURA Biosciences, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| TuHURA Biosciences, Inc. | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA register name IFx-Hu2.0 (also registered as PAc/emm55) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is TuHURA Biosciences, Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IFx-Hu2.0 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IFx-Hu2.0 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IFx-Hu2.0 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.